Evidence map›Paper›PMID 42188343›Full record

ArticleJournal of personalized medicine2026

Promises and Pitfalls of Whole Exome Sequencing in Therapy-Resistant Chronic Thrombocytopenia in Childhood: A Case Report.

Eszter Györke, Gábor Benyó, Kristóf Balázs Árvai, Csaba Bödör, László Kereskai, Hajnalka Ábrahám, Barbara Réger, Bálint Egyed, Gábor Ottóffy

Abstract readCase Reports
In one paragraph

Article in Journal of personalized medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Eszter GyörkeDepartment of Pediatrics, Markusovszky Teaching University Hospital, 9700 Szombathely, Hungary.
Gábor BenyóDepartment of Pediatrics, Markusovszky Teaching University Hospital, 9700 Szombathely, Hungary.
Kristóf Balázs ÁrvaiHAS-SU Momentum Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, 1085 Budapest, Hungary.ORCID 0000-0001-8774-937X
Csaba BödörHAS-SU Momentum Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, 1085 Budapest, Hungary.ORCID 0000-0002-0729-692X
László KereskaiInstitute of Pathology, University of Pécs Medical School, 7624 Pecs, Hungary.
Hajnalka ÁbrahámIstván Ábrahám Nano-Bioimaging Center, Central Electron Microscopic Laboratory, University of Pécs Medical School, 7624 Pecs, Hungary.
Barbara RégerDepartment of Laboratory Medicine, University of Pécs Medical School, 7624 Pecs, Hungary.
Bálint EgyedPediatric Center, Semmelweis University, 1085 Budapest, Hungary.ORCID 0000-0001-8783-9025
Gábor OttóffyDepartment of Pediatrics, University of Pécs Medical School, 7624 Pecs, Hungary.ORCID 0000-0002-8990-6620

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe etiological diagnosis of chronic thrombocytopenia in children remains challenging and is often established by exclusion. In this article, we present the case of a patient in whom we used whole-exome sequencing (WES) to help identify the underlying cause and determine the appropriate treatment.

methodsWhole-exome sequencing was performed to clarify the genetic background of the disease. Based on the results, transmission electron microscopy (TEM) was also carried out to confirm or exclude the pathogenic role of the identified

resultsIn this patient, despite the presence of the

conclusionsOur case highlights that WES testing, which is emerging in pediatric hematology practice, offers not only diagnostic advantages but also pitfalls. Whole-exome sequencing has recently emerged as a new diagnostic tool and has been available nationwide in pediatric hematology-oncology care in Hungary for just over two years. While personalized treatment strategies for benign hematologic diseases increasingly rely on high-throughput genetic testing, the clinical application of WES requires a cautious, critical evaluation of results. Despite the method's promise, the heterogeneity of the findings underscores the need to interpret WES results carefully and to place them in a clinical context in every case.

Indexed as

gray platlet syndrome (GPS)immune thrombocytopenia (ITP)inherited thrombocytopeniapediatric hematologypersonalized therapythrombocytopeniawhole exome sequencing (WES)

Identifiers

PMID42188343
PMCPMC13208811

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.